Radotinib induces CD11b<sup>+</sup>Annexin V<sup>+</sup> cells in AML cell lines.

<p>Cells were incubated with various concentrations of radotinib and/or ATRA for 72 h, harvested and immunostained with anti-human antibodies against CD11b and Annexin V, as described in the Methods. (A) NB4. (B) HL60. (C) Kasumi-1. (D) THP-1. (E) The CD11b<sup>+</sup>Annexin V<sup>+</sup> cells in HL60. (F) Annexin V<sup>+</sup> in the CD11b<sup>+</sup> gated cells. (G) Schedule of differentiation induced cell death (plans A, B, C and D). (H) Cell death data by the respective plan. Data represent the mean ± SEM. Statistically significant differences from the DMSO-treated control (*) or ATRA treatment (#) are denoted as follows.*, #: <i>P</i> < 0.05; **, ##: <i>P</i> < 0.01; ***, ###: <i>P</i> < 0.001. Rd, radotinib; Das, dasatinib; ATRA, all-trans retinoic acid.</p>